Kristina Jankovic, MD
@JankovicK
Followers
954
Following
2K
Media
98
Statuses
355
🎀Medical oncology resident, PhD student, @ESOncology fellow, @OncoAlert AF | 🏩 Oncology clinic, University Clinical Center Nis #oncology #breastcancer🎀
Nish, Republic of Serbia
Joined December 2016
🚨 The full #OncoAlertColloquium is NOW available ON DEMAND! 🚨. 🎥 Just click & watch - no registration required!. Access here 👉👉 👈👈.
THE COMPLETE #OncoAlertColloquium 🚨 ON DEMAND, JUST CLICK & WATCH.ACCESS HERE 👉 👉 👈👈 . NO REGISTRATION NEEDED‼️ .The Breakdown of the 2024 colloquium. DAY 1 (GU Oncology). DAY 2 (Thoracic Oncology)
1
2
10
🧠 Always informed with the @OncoAlert 🚨 Weekly Round Up | . This week in #BreastCancer 🎀:.✅ PRIM-B: Prognostic ctDNA model in metastatic disease.✅ Breastfeeding after BC in young #BRCA🧬 carriers – new insights. 🔗 Stay updated:
The OncoAlert🚨Weekly Round Up .Covering the TOP of the week July 4-10, 2025 . REGISTER at OR . Discussing:.✅News From Industry: durvalumab in #BladderCancer.✅PRIM-B in metastatic #BreastCancer .✅Breastfeeding after breast
0
3
12
🧴 Prophylactic skincare (MD meds + pharmacist education + nurse-led care) in NSCLC pts on #Nivo + #Ipi ± chemo led to .↓ skin toxicities (21%➡8%), .↓ steroid use (36%➡10%), .↓ discontinuation (21%➡4%). 🔗 @OncoAlert #SupportiveCare #Immunotherapy
0
4
20
Phase 2 trial in pretreated recurrent/metastatic #CervicalCancer shows camrelizumab + famitinib improves outcomes 🆚 camrelizumab alone or chemo. 🎯 ORR: 41.0% 🆚 24.1% 🆚 14.3%.⏱️ PFS: 8.1 🆚 4.1 🆚 2.9 mo.💥 OS: 20.2 🆚 14.9 🆚 13.9 mo. 🔗 @OncoAlert
0
2
15
💡 Very important overview of side effects of new and emerging #BreastCancer 🎀 therapies 💊 💉 in the @ASCO Educational Book 📚 ✨. 🔗 @OncoAlert .#Toxicity #EndocrineTherapy #TargetedAgents
1
12
34
🆕 in @TheLancetOncol :.In the STAMPEDE phase 3 trial, metformin in non-diabetic 👨with metastatic hormone-sensitive #ProstateCancer starting #ADT showed:. ❌ no OS benefit (67.4 vs. 61.8 mo; HR 0.91).✅ ↓ metabolic effects of ADT.⚠️ ↑ GI AEs gr ≥3 . 🔗
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol out on Lancet Oncology. . In the STAMPEDE phase 3 trial, researchers evaluated whether adding
0
1
8
✨ This week’s #JournalClub by @OncoAlert & @VJOncology brings us 🇮🇹 @Icro_Meattini discussing Multimodal De-Escalation in Early #BreastCancer 🎀, on the @ASCO Educational Book 📘. Link to publication: 👇.🔗
The @OncoAlert @VJOncology JOURNAL CLUB .This week we have the pleasure to bring you @Icro_Meattini 🇮🇹of the University of Florence. Discussing: Multimodal De-Escalation Strategies in Early Breast Cancer on the @ASCO Educational Book. Direct Link to Publication
0
3
7
#SupportiveCare in #BreastCancer 🎀. 🌸 #Elinzanetant, a neurokinin-targeted therapy, significantly reduced vasomotor symptoms in women with #BC on endocrine therapy 👇. 🔗 @OncoAlert @NEJM
1
9
26
#Immunotherapy in #GynOnc . 🍀 Nivolumab ➕ ipilimumab in advanced gynecological clear cell cancers (CCCs ).(MoST‑CIRCUIT phase 2 nonRCT).👇. 👩🦰 N=28 |⏳mFU 11.2 months.✅ ORR 54%.✅ 6‑mo PFS 58%.✅ mDOR & mOS not reached. 🔗 @OncoAlert @JAMAOnc
0
7
25
RT @realbowtiedoc: Truly a #legacy podcast for me as this was the last conversation I had with my dear #mentor and #hpm friend the late Dr….
0
7
0
RT @realbowtiedoc: Excited to head out this week to share the #BestofASCO in #pallonc and #supponc later this week. Join us! . https://t.co….
0
7
0
#AIinMedicine .In a study of 362 #BreastCancer cases, ChatGPT 🤖 matched expert consensus in 46%, with only 39% response consistency. ⚠️Lower accuracy in stage IV, molecular/genetic & #ADC cases. ⚠️ 68% varied in detail & format. 🔗 @OncoAlert @JCO_ASCO
2
13
51
🆕 in @JAMAOnc :💣 The U-BOMB Phase 2 Non-RCT:. Utidelone ➕ Bevacizumab for ERBB2-negative #MetastaticBreastCancer 🎀with active #BrainMetastases 🧠. 👩 N=47.✅ CNS ORR: 42.6%.📊 Median PFS: 7.7 months.⚠️ Manageable toxicity. 🔗 @OncoAlert
1
3
15
🎵 Self-selected music during chemo doesn’t help only patients - it also increases positive mood 😊 and reduces distress 😌 in caregivers. 🍀 🎶. 💸 Low-cost ✅.⚠️ Low-risk ✅.🔝 High-impact ✅. Read more: 🔗 @OncoAlert #SupportiveCare 🎀 @JCO_ASCO
0
11
30
PADA-1 trial (n=369 pts, advanced ER+/HER2- #BreastCancer):. 🧬 ctDNA detected in 91% at baseline, 76% at cycle 2 ET+CDK4/6 inh. 📉 Baseline & early dynamic ctDNA changes predicted PFS & OS. 🔝 ctDNA-based risk model improves upon RECIST. @OncoAlert .🔗
0
10
24
📊 Meta-analysis of 23 RCTs (14,000 pts) on novel #BreastCancer therapies shows ❌ NO significant PFS difference between 👩🏻🦳 Whites (HR 0.62), 👩🏽 Asians (HR 0.54) and 👩🏿 Blacks (HR 0.54). 🌍 Results support broad applicability. 🔗 @OncoAlert
0
5
13
JCOG1017 (PRIM-BC) trial: Primary tumor resection in de novo stage IV #BreastCancer . ❌ No OS benefit (75 🆚 69 mo; HR 0.86; p=0.13). ✅ improved local RFS (63 🆚 20 mo; HR 0.42; p < 0.0001). 💡Possible OS benefit in premenopausal pts & single-organ mets.
Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial . . In a randomized study of 407 patients with de novo stage IV #BreastCancer , primary tumor
0
5
17
🆕 #OncoAlert Newsletter is out! ☄️ . Covering the latest trials across #BreastCancer, #GEJ, #NSCLC 🫁, #ProstateCancer & more. Don’t miss the FORTITUDE-101 update, U-BOMB, DADSPORT, and more. 💡 . 👉Register here:
The OncoAlert🚨Newsletter Now Out !! .Covering June 23-July 3, 2025 . REGISTER at OR Discussing:.✅Update on FORTITUDE-101 (Industry) GEJ.✅ShortHER in #BreastCancer.✅U-BOMB Trial in Breast #Cancer.✅DADSPORT in
0
1
11
🚨 Groundbreaking news in #BladderCancer! 💥 . Imfinzi approved ✅ in the EU as first perioperative immunotherapy for resectable MIBC based on #NIAGARA trial results: .✅ 32% lower risk of recurrence/progression/death .#GUonc.👇.
News From Industry.Source: AstraZeneca. The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) as the first and only perioperative immunotherapy for resectable muscle-invasive #BladderCancer (MIBC), based on results from the Phase III NIAGARA trial. In
2
2
14
Fantastic overview by @CathyEngMD! 🔥 A perfect way to kick off #ESMOGI25 – don’t miss these key updates in #colorectalcancer and anal cancer! 👇 #GIonc.
What A great week for GI Onc with #ESMOGI25 🚨. To prepare us, here is our faculty @CathyEngMD .who covers the Top Trials of the last year in #colorectalcancer & Anal Cancers . GI Faculty.@pashtoonkasi.@GillSharlene .@CathyEngMD.@marklewismd.@AndresC27622123.@manjuggm
0
4
8
Don’t miss this week’s @OncoAlert @VJOncology Journal Club!. 💡 An insightful discussion led by @KoheiShitara 🇯🇵 on the NEJM paper comparing trastuzumab deruxtecan 🆚 ramucirumab + paclitaxel in gastric cancer. 🔗
The @OncoAlert @VJOncology JOURNAL CLUB. This week we have the pleasure to bring you our OncoAlert Colleague @KoheiShitara 🇯🇵Discussing his paper:. Trastuzumab Durextecan or Ramucirumab plus paclitaxel in gastric cancer out on NEJM. #OncoAlertAF
0
2
9